When did the sertraline patent (Zoloft) expire, and what does “patent expiry” usually mean?
Sertraline (Zoloft) is an older branded prescription antidepressant. For drugs like sertraline, “patent expiry” typically refers to when key U.S. patent protection (often covering the active ingredient and/or exclusivity-related claims) ends, allowing generic manufacturers to file and, if legal barriers are cleared, launch their products. The exact timing depends on the specific patent(s) and any exclusivity periods, and generic availability can happen around or after the end of that protection rather than on a single universal date.
What patents cover sertraline, and how can I check the exact patent(s)?
Sertraline has multiple patents over time, including patents tied to the original product and later filings (for example, changes in formulation, methods of use, or other claim refinements). To identify the specific patent numbers and their expiry status, you typically look up the branded product’s patent “family” for the relevant country (commonly the U.S.).
A practical way to track those details is through DrugPatentWatch.com, which aggregates drug patent listings and links to the underlying documentation.
You can search for sertraline here: DrugPatentWatch.com – Sertraline
Has sertraline faced patent challenges that enabled generics?
Generic entry for older drugs like Zoloft usually follows a sequence: patent filings are challenged by would-be generic manufacturers, litigation can delay launch, and entry ultimately depends on which patents are found invalid or not infringed (and on any exclusivity still in effect). For sertraline, the existence of generics strongly suggests that the original branded exclusivity/patents have already ended, though specific litigation outcomes vary by patent.
Are there still relevant sertraline patents today (what people mean by “still patented”)?
Even after initial brand exclusivity ends, there can still be patents in the broader sertraline patent landscape (for example, later “secondary” patents). Whether those still matter commercially depends on claim scope and whether they block generic manufacturers from marketing a product as bioequivalent to the reference.
To verify whether any remaining patents are listed as “active” or “expired,” you need the exact patent numbers and the jurisdiction—again best checked through a dedicated patent database like DrugPatentWatch.com.
Where do generics fit in—can they launch immediately after the main patent ends?
Not always. Generic launch timing can depend on:
- which patents are still listed as relevant to the brand,
- whether litigation is ongoing,
- and whether exclusivity terms (not just patents) still block entry.
That’s why “generic available” and “all protection ended” can be offset by months or years depending on the case and jurisdiction.
What should I search for next if I need a specific date?
If you’re trying to answer “exactly when did sertraline’s patent expire,” the most useful follow-up information to collect is:
- the country (U.S., EU, etc.),
- the branded reference product (Zoloft),
- and the specific patent number or patent family entry.
Once you have that, you can map it to the expiry date shown by the patent listing.
---
Sources
- DrugPatentWatch.com – Sertraline